(Q38023761)

English

Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma

scientific article published on July 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

author name string

Kevin W Lor

1

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Pieter J Helmons

2

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Helen Belew

3

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

James R Lane

4

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Edward D Ball

5

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

language of work or name

0 references

publication date

1 July 2012

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Pharmacotherapy

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

32

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

596-603

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantatio

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01096.X

21 January 2018

Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01096.X

21 January 2018

Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-stimulating factor and granulocyte-colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01096.X

21 January 2018

Management strategies for the hard-to-mobilize patient

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01096.X

21 January 2018

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01096.X

21 January 2018

Cost and Clinical Analysis of Autologous Hematopoietic Stem Cell Mobilization with G-CSF and Plerixafor Compared to G-CSF and Cyclophosphamide

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01096.X

21 January 2018

Identifiers

10.1002/J.1875-9114.2012.01096.X

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

release_3ostagcesbbdvkkcwyyj3svyge

1 reference

https://api.fatcat.wiki/v0/release/3ostagcesbbdvkkcwyyj3svyge

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38023761&oldid=1841504676"